PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call

Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call

MENLO PARK, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial Results on Wednesday, May 6, 2020, at 4:30pm Eastern Time.

The call will be webcast and may be accessed at Pacific Biosciences’ website at:  .

Date:  May 6, 2020

Time:  4:30pm ET

Listen via Internet: 

Toll-free:  888.366.7247

International:  707.287.9330

Conference ID: 5453089

Replay: 

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at .

Contact:  Pacific Biosciences

Trevin Rard

650.521.8450

EN
27/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE

PacBio Board Independent Investigation Concludes Allegations Unsubstan...

PacBio Board Independent Investigation Concludes Allegations Unsubstantiated MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the i...

 PRESS RELEASE

PacBio Announces First Quarter 2025 Financial Results

PacBio Announces First Quarter 2025 Financial Results MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating e...

 PRESS RELEASE

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newbo...

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand Collaboration leverages HiFi’s unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as pa...

 PRESS RELEASE

PacBio Announces Plans to Improve Methylation Detection in HiFi Chemis...

PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Den...

 PRESS RELEASE

Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner f...

Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), a global initiative to prevent Alzheimer’s disease and improve brain health, today announced that PacBio (NASDAQ: PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch